Linezolid is indicated for the treatment of drug-resistant severe nosocomial or community-acquired pneumonia and skin and soft-tissue infections caused by Gram-positive bacteria.1 Its ability to effectively penetrate into the CSF makes it a valuable salvage therapy for CNS infections.2–12 However, there is significant inter- and intra-individual variability in linezolid concentrations, particularly in critically ill patients, potentially resulting in subtherapeutic drug exposure.2–4,6,7,10,12...
